1. Home
  2. WST vs BIIB Comparison

WST vs BIIB Comparison

Compare WST & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Pharmaceutical Services Inc.

WST

West Pharmaceutical Services Inc.

HOLD

Current Price

$254.23

Market Cap

17.9B

Sector

Health Care

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$176.91

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WST
BIIB
Founded
1923
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9B
27.1B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
WST
BIIB
Price
$254.23
$176.91
Analyst Decision
Buy
Buy
Analyst Count
7
28
Target Price
$319.43
$197.46
AVG Volume (30 Days)
788.3K
846.3K
Earning Date
04-23-2026
04-30-2026
Dividend Yield
0.35%
N/A
EPS Growth
1.49
N/A
EPS
6.79
8.79
Revenue
$2,886,900,000.00
$9,890,600,000.00
Revenue This Year
$6.76
N/A
Revenue Next Year
$6.15
N/A
P/E Ratio
$37.59
$20.17
Revenue Growth
1.95
2.22
52 Week Low
$187.43
$110.04
52 Week High
$322.34
$202.41

Technical Indicators

Market Signals
Indicator
WST
BIIB
Relative Strength Index (RSI) 60.61 41.35
Support Level $253.53 $170.99
Resistance Level $261.98 $184.16
Average True Range (ATR) 7.31 4.87
MACD 1.78 -0.54
Stochastic Oscillator 85.46 28.57

Price Performance

Historical Comparison
WST
BIIB

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: